Regeneron begins COVID-19 antibody cocktail late-stage trial

Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.

The trial, run jointly with the National Institute of Allergy and Infectious Diseases, would test the therapy's ability to prevent infection in those who have had close exposure to a COVID-19 patient.